- Home
- GROV vs ONCO Comparison
GROV vs ONCO Comparison
Compare GROV & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROV
- ONCO
- Stock Information
- Founded
- GROV 2016
- ONCO 2018
- Country
- GROV United States
- ONCO United States
- Employees
- GROV N/A
- ONCO N/A
- Industry
- GROV Package Goods/Cosmetics
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- GROV Consumer Discretionary
- ONCO Health Care
- Exchange
- GROV Nasdaq
- ONCO Nasdaq
- Market Cap
- GROV 50.6M
- ONCO 48.5M
- IPO Year
- GROV N/A
- ONCO 2022
- Fundamental
- Price
- GROV $1.39
- ONCO $5.21
- Analyst Decision
- GROV Buy
- ONCO
- Analyst Count
- GROV 1
- ONCO 0
- Target Price
- GROV $2.00
- ONCO N/A
- AVG Volume (30 Days)
- GROV 152.5K
- ONCO 2.0M
- Earning Date
- GROV 11-07-2024
- ONCO 11-15-2024
- Dividend Yield
- GROV N/A
- ONCO N/A
- EPS Growth
- GROV N/A
- ONCO N/A
- EPS
- GROV N/A
- ONCO N/A
- Revenue
- GROV $227,251,000.00
- ONCO $1,463,746.00
- Revenue This Year
- GROV N/A
- ONCO N/A
- Revenue Next Year
- GROV $5.97
- ONCO N/A
- P/E Ratio
- GROV N/A
- ONCO N/A
- Revenue Growth
- GROV N/A
- ONCO N/A
- 52 Week Low
- GROV $1.19
- ONCO $2.80
- 52 Week High
- GROV $2.49
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- GROV 55.14
- ONCO 52.51
- Support Level
- GROV $1.28
- ONCO $5.45
- Resistance Level
- GROV $1.59
- ONCO $6.50
- Average True Range (ATR)
- GROV 0.09
- ONCO 0.50
- MACD
- GROV 0.02
- ONCO 0.08
- Stochastic Oscillator
- GROV 39.42
- ONCO 53.36
About GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.